Indian wellness startup Okay&L Wellness Technology scores $4M in seed funding
Okay&L Wellness Technology, a well being expertise startup in India, has bagged Rs 30 crore ($4 million) from angel buyers to launch its wellness app.
According to a news report, the corporate seeks to redefine wellness by way of science-based personalised options.
Okay&L Wellness, also called RESET Tech, gives therapeutic-based well being options to way of life troubles utilizing pure, sustainable, and conventional strategies of yoga and meditation.
It targets to roll out its wellness platform by “early next quarter,” mentioned co-founder Karan Talreja.
The seed spherical was participated by Vimal Kedia and Surendra Kedia of Manjushree Ventures and Narendra Firodia of the Sohamm Group.
Intellect extends free limited-time entry to self-care app, assets
Intellect, a Singapore-based psychological well being startup, has began providing a free six-month premium subscription to its self-care app and assets for shoppers and companions of non-profit organisation Care Corner Singapore.
Available now till the top of May subsequent yr, the providing targets Singapore’s center and low-income communities whose psychological well-being was closely impacted by the continued COVID-19 pandemic. They additionally lack vast entry to reasonably priced psychological healthcare, in response to Intellect co-founder and CEO Theodoric Chew.
In tandem with Care Corner’s one-on-one psychological well being counselling providers, Intellect will present in-app modules and programmes that cowl a variety of subjects, comparable to fundamental psychological well being assist, nervousness, fear, assertiveness and vanity. Some of those modules and programmes embody studying paths, rescue classes, well-being check-in, analytics, in addition to guided journaling.
Intellect may also be giving beneficiaries free entry to its month-to-month webinar collection, Intellearn, and will likely be conducting on-line workshops to assist customers get familiarised with its app and help them in integrating the educational paths and rescue classes of their private lives.
Lunit secures US FDA approvals for AI chest x-ray and mammography diagnostic instruments
South Korea-headquartered medical AI supplier Lunit has obtained the US Food and Drug Administration’s 510(ok) clearance for each its AI options for chest x-ray and mammography.
Lunit INSIGHT MMG analyses mammography photographs and detects the situation of lesions indicative of breast most cancers, together with offering an abnormality rating. This gadget is skilled utilizing over 240,000 mammography circumstances, together with round 50,000 breast most cancers circumstances. It was beforehand cleared in Europe upon receiving a CE mark.
Meanwhile, Lunit INSIGHT CXR Triage is a triage and notification software program that analyses chest x-ray photographs. It is designed to prioritise emergent circumstances comparable to pleural effusion and pneumothorax following examinations to shortly notify clinicians about findings and thus reducing analysis time for pressing circumstances. This gadget is skilled utilizing greater than 160,000 chest radiographs with CT photographs. It has proven round 94%-96% sensitivity and 95%-99% specificity on pleural effusion and pneumothorax.
Sky Labs brings wearable coronary heart monitoring gadget to Britain
South Korean medical expertise startup Sky Labs is rolling out its AI-powered wearable coronary heart monitoring gadget known as CART-I.
It has obtained a CE-MDD approval in Europe, allowing the usage of the gadget for atrial fibrillation monitoring and illness diagnoses throughout the area.
Sky Labs famous Britain’s medical digitalisation that prompted the “sharp growth” of telemedicine and cellular well being markets there, opening a chance for the startup with the rise in curiosity in modern well being merchandise.
The ring-type CART-I mechanically measures atrial fibrillation and coronary heart charge around the clock. It makes use of ECG to gather exact cardiac alerts, in addition to a PPG sensor for steady atrial fibrillation monitoring with out intervention.
Collected information are transmitted to a cloud platform the place these are processed by AI into insights and despatched again each to the person’s app and their physician’s platform. The information assist medical professionals kind an correct analysis of their sufferers’ situations.
In June, Sky Labs obtained $20 million in a Series B investing spherical, which was deployed for the event of latest monitoring units for various continual illnesses, for buying market approvals, and for manpower recruitment.
Terumo, Diabeloop signal deal to ship automated insulin supply options to Europe
Terumo Corporation, a Tokyo-based medical expertise agency, and French therapeutic AI remedy gadget maker Diabeloop have partnered to increase their options for diabetic sufferers in Europe.
They agreed to market their automated insulin supply (AID) system with a possible for additional world enlargement.
Used for insulin-dependent diabetes administration, the AID system automates and personalises the remedy of diabetes. A self-learning algorithm known as DBLG1 developed by Diabeloop is related to a steady glucose monitor and an insulin pump by Terumo. It analyses information in real-time and is ready to both keep present insulin settings or regulate insulin supply.
The two firms have been creating the AID system since 2020 with an preliminary purpose to focus on Japanese sufferers.
“Together with Diabeloop, we are confident that we will be able to provide healthcare professionals and patients with value-added solutions not only in Japan but for all corners of the world,” mentioned Hikaru Samejima, president of Terumo’s General Hospital Company.
“We are thrilled to reinforce our partnership with global leader Terumo with this new agreement and expand our contribution to personalised diabetes management via Diabeloop’s interoperable solution,” Marc Julien, co-CEO of Diabeloop, additionally mentioned.
US-based Labcorp opens bioanalytical lab in Singapore
American life sciences firm Labcorp has opened an built-in bioanalytical laboratory in Singapore.
Its newest Asia Pacific facility will likely be co-located with the corporate’s Central Laboratory Services and Clinical Development and Commercialization Services, strengthening its laboratory community within the area.
According to a press launch, the brand new bioanalytical laboratory will supply bioanalysis, liquid chromatography-mass spectrometry and immunochemistry platforms, in addition to scientific biomarker analytical providers.
The all-in-one facility will present shoppers with “faster turnaround times” for information in early part trials performed throughout the area, mentioned Labcorp Drug Development CEO Dr Paul Kirchgraber.
“Singapore serves as a strategic location from which Labcorp can increase accessibility by offering regional and international clients comprehensive support for their bioanalytical studies,” Kirchgraber acknowledged.